Appili Therapeutics’ C$7 Million Rights Offering

McCarthy Tétrault advised the syndicate of agents in connection with Appili Therapeutics’ offering.

Appili Therapeutics Inc. closed its previously announced public offering of units.

Pursuant to the Offering, Appili Therapeutics Inc. issued a total of 8,434,000 units at a price of $0.83 per unit for aggregate gross proceeds of C$7,000,220. Each unit is comprised of one Class A common share of Appili Therapeutics Inc.(Common Share) and one-half of one Common Share purchase warrant of Appili Therapeutics Inc.  

The Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. and including iA Private Wealth Inc., Leede Jones Gable Inc., Research Capital Corporation, and Richardson Wealth Limited and Appili Therapeutics Inc..

Appili Therapeutics Inc. (TSE:APLI) is an infectious disease biopharmaceutical company. 

The McCarthy Tétrault team was led by Philippe Leclerc (Picture) and Mireille Trottier (Business).

Involved fees earner: Philippe Leclerc – McCarthy Tétrault; Mireille Trottier – McCarthy Tétrault;

Law Firms: McCarthy Tétrault;

Clients: Appili Therapeutics; Bloom Burton & Co. Limited; iA Private Wealth Inc.; Leede Jones Gable Inc; Research Capital Corporation; Richardson Wealth Limited;

Sonia Carcano

Author: Sonia Carcano